Xanomeline is a muscarinic receptor agonist active ingredient used in the fixed-dose product Cobenfy (xanomeline and trospium chloride), which is FDA-approved for schizophrenia in adults. In this combination, xanomeline provides central M1/M4-preferring agonist activity while trospium limits peripheral muscarinic effects. The approved clinical indication is tied to the combination product.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
